Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EBIT (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed EBIT for 11 consecutive years, with -$794437.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 77.95% year-over-year to -$794437.0, compared with a TTM value of -$8.1 million through Sep 2025, down 294.25%, and an annual FY2024 reading of $4.5 million, up 135.83% over the prior year.
  • EBIT was -$794437.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$2.4 million in the prior quarter.
  • Across five years, EBIT topped out at $13.2 million in Q1 2024 and bottomed at -$6.4 million in Q4 2021.
  • Average EBIT over 5 years is -$2.1 million, with a median of -$2.6 million recorded in 2024.
  • The sharpest move saw EBIT crashed 444.73% in 2021, then surged 789.85% in 2024.
  • Year by year, EBIT stood at -$6.4 million in 2021, then surged by 41.88% to -$3.7 million in 2022, then grew by 21.35% to -$2.9 million in 2023, then grew by 11.94% to -$2.6 million in 2024, then skyrocketed by 69.02% to -$794437.0 in 2025.
  • Business Quant data shows EBIT for KPRX at -$794437.0 in Q3 2025, -$2.4 million in Q2 2025, and -$2.3 million in Q1 2025.